Metformin (Longevity Context): Benefits, Dosage, Forms & Research

What the Research Says

Metformin's longevity potential is supported by strong observational data but lacks definitive interventional proof in non-diabetics. Bannister et al. (2014) published the landmark observational finding of 15% mortality reduction. The TAME trial (Targeting Aging with Metformin), led by Nir Barzilai, is the first FDA-approved trial specifically testing an anti-aging drug in humans — it will track composite age-related outcomes in ~3,000 participants aged 65-79. Gandini et al. (2014) meta-analyzed the cancer risk reduction data. The key controversy is Konopka et al. (2019), who showed metformin blunted exercise-induced mitochondrial improvements — raising questions about whether metformin's AMPK activation might compete with exercise's AMPK activation. This is a prescription medication and should only be used under medical supervision.

Benefits of Metformin (Longevity Context)

• Longevity association — Bannister et al. (2014) analyzed UK Clinical Practice Research Datalink data and found that type 2 diabetics on metformin had 15% lower all-cause mortality than matched non-diabetic controls, suggesting benefits beyond glucose control
• AMPK activation and mTOR inhibition — metformin activates AMP-activated protein kinase and inhibits mTOR complex 1, engaging two of the most critical longevity pathways that also mediate caloric restriction's benefits
• Cancer risk reduction — multiple observational studies and meta-analyses show metformin users have 30-40% lower incidence of several cancers including breast, colorectal, and pancreatic cancer (Gandini et al., 2014)
• Anti-inflammatory — metformin reduces CRP, TNF-α, and IL-6, and inhibits NF-κB signaling, addressing the chronic low-grade inflammation ("inflammaging") that drives age-related disease
• Cardiovascular protection — the UKPDS trial demonstrated metformin reduced cardiovascular events by 39% in overweight type 2 diabetes patients independently of glucose control

Side Effects and Safety

Safety profile: Safe with Caution

Potential Side Effects

• GI symptoms — diarrhea, nausea, bloating, and abdominal cramping affect 20-30% of users; extended-release reduces these
• Vitamin B12 depletion — long-term metformin use reduces B12 absorption by up to 30%; supplement B12 and monitor levels
• Lactic acidosis — extremely rare but serious; risk increases with kidney impairment, alcohol use, and dehydration
• Metallic taste in mouth
• May blunt exercise adaptations — Konopka et al. (2019) found metformin attenuated mitochondrial and cardiorespiratory improvements from aerobic exercise in older adults

Drug & Supplement Interactions

• Alcohol — increases lactic acidosis risk; moderate use only
• Contrast dye (for CT scans) — metformin must be held before and after iodinated contrast to prevent lactic acidosis
• Kidney-affecting medications — metformin is renally cleared; drugs that impair kidney function increase toxicity risk
• Insulin and sulfonylureas — additive hypoglycemia risk
• Exercise — may attenuate some exercise-induced mitochondrial adaptations; some practitioners cycle metformin around intense training